The technology, which is patent pending, can be used to help identify cancer patients who would respond to immune checkpoint inhibition treatment.
The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.
The company has been working with NGS-based ctDNA testing for some time in research, but has now made its first move into the clinical sphere.
The Johns Hopkins University spinout has shifted from being research-oriented to focusing on bringing clinical tests through regulatory requirements.
The companies will work together to develop two next-generation sequencing-based in vitro cancer diagnostics.
In addition to its clinical trials matchmaking service, Cure Forward offers a platform for cancer patients to access and share their genomic test data.
The company said it anticipates rapid growth and intends to move to a new Baltimore facility in 2016.
The convertible note funding is part of a larger Series A round currently underway.
Despite the findings of the Hopkins study, for practical and economic reasons many diagnostic laboratories currently only sequence tumor samples or do not believe the tumor-normal approach is necessary.
N-of-One will provide clinical interpretation services for genomic tests conducted as part of the New England Veterans' Integrated Service Network oncology program
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.